Micro Interventional Devices, Inc.™ (MID), an emerging cardiovascular medical device company, announced today that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal™. The patient is the first to be enrolled in the company’s STASIS clinical trial that has commenced in Europe.